NeuroClues vs Qureight (2026): Pricing, Features & Which to Choose

Who comes out ahead

Based only on the facts in our directory. The right pick still depends on the job you need done.

Lower starting price
Not comparable
Not comparable: NeuroClues does not list a price
Free plan
Tie
Neither has one
Higher rating
NeuroClues
4.3 against 4.1
Same job?
Yes
Both are Healthcare AI tools

Side by side

Compared on	NeuroClues	Qureight
Our rating	4.3Better	4.1
Starts at	Not listed	Not listed
Free plan	No	No
Category	Healthcare AI	Healthcare AI
Plans	See pricing	See pricing
Key features	Portable, CE-marked Class IIa medical device for clinical eye-movement recording Calibration-free patient setup using dual infrared cameras at 400 fps AI-derived biomarkers benchmarked against reference ranges for clinical interpretation Early-detection targeting for Parkinson's, Alzheimer's, and multiple sclerosis Deployment across university hospitals and private neurology practices in seven-plus countries	Deep-learning lung imaging biomarkers Lung8, Air8 and Fibr8 Glass8 and Vascul8 for vascular and parenchymal measures Central reads and endpoint discovery for trials Imaging data curation and quality control Built for pulmonary fibrosis, hypertension and bronchiectasis trials
Pros	CE-marked Class IIa medical device status gives it real regulatory clearance, not only research-stage promise More than €22 million raised, including a €10 million Series A, signals investor confidence Aims at detection years before visible symptoms, where neurological treatment has the most impact	Consistent measurement reduces the variability that costs trial power Named biomarkers rather than a generic imaging claim Focused deeply on respiratory and cardiac disease
Cons	No published pricing, and as a clinical device it is sold directly to institutions, not individuals Limited so far to the European market and CE marking, without confirmed FDA clearance As a diagnostic aid, findings still require a neurologist's clinical interpretation, not a standalone verdict	No published pricing; sold to trial sponsors Biomarkers need regulatory acceptance per context of use Narrow therapeutic focus by design
Company	neuroClues, founded 2020	Qureight Ltd

Prices come from each vendor's pricing page, last checked 20260814. Check the vendor before you buy.

FAQ

Questions people ask

Is NeuroClues better than Qureight?

In our reviews NeuroClues scores 4.3 and Qureight scores 4.1. The better pick depends on the job. NeuroClues: Eye-tracking medical device that uses AI to detect early biomarkers of Parkinson's, Alzheimer's, and multiple sclerosis. Qureight: Imaging biomarkers for lung and heart clinical trials, from a Cambridge deep-learning lab.

Which is cheaper, NeuroClues or Qureight?

NeuroClues: see pricing. Qureight: see pricing.

Do NeuroClues and Qureight have free plans?

Neither lists a free plan.

More comparisons

NeuroClues compared with

All NeuroClues alternatives

Qureight compared with

All Qureight alternatives